<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02450968</url>
  </required_header>
  <id_info>
    <org_study_id>EK15-2015</org_study_id>
    <nct_id>NCT02450968</nct_id>
  </id_info>
  <brief_title>Altitude Related Illness In Patients With Respiratory Disease</brief_title>
  <official_title>Dexamethasone for Prophylaxis of Acute Mountain Sickness in Patients With Chronic Obstructive Pulmonary Disease Travelling to Altitude</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center of Cardiology and Internal Medicine, Kyrgyzstan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, placebo controlled trial evaluating efficacy of dexamethasone in preventing acute
      mountain sickness in lowlanders with chronic obstructive lung disease travelling from 700 m
      to 3200 m.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, placebo-controlled, double-blind parallel trial evaluating the efficacy
      of dexamethasone prophylaxis in reducing the incidence of acute mountain sickness in
      lowlanders with chronic obstructive pulmonary disease travelling to altitude. Participants
      living in the Bishkek area, Kyrgyzstan (700m), will be transferred by car within 4h to the
      Tuja Ashu high altitude clinic (3200 m), and stay there for 2 days. Dexamethasone 2x4mg/day
      (or placebo), will be administered before departure at 700 m and during the stay at altitude.
      Outcomes will be assessed during the stay at 3200 m.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute mountain sickness, cumulative incidence</measure>
    <time_frame>day 3 at 3200 m</time_frame>
    <description>Difference between dexamethasone and placebo group in cumulative incidence of acute mountain sickness assessed by the environmental symptoms questionnaire cerebral subscale (score &gt;=0.7)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severe hypoxemia</measure>
    <time_frame>day 1 to 3 at 3200m</time_frame>
    <description>Number of participants in the dexamethasone and placebo group with arterial oxygen saturation measured by pulse oximetry less than 75% for more than 30 min or less than 70% for more than 15 min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute mountain sickness, severity</measure>
    <time_frame>day 1, day 2, day 3 at 3200 m</time_frame>
    <description>Difference between dexamethasone and placebo group in the acute mountain sickness severity assessed by the environmental symptoms questionnaire cerebral subscale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 min walk distance</measure>
    <time_frame>Day 2 at 3200 m</time_frame>
    <description>Difference in the distance walked in 6 min between the dexamethasone and placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived exertion</measure>
    <time_frame>Day 2 at 3200 m</time_frame>
    <description>Difference in the perceived exertion rated with the Borg CR10 scale between the dexamethasone and placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spirometry</measure>
    <time_frame>Day 2 at 3200 m</time_frame>
    <description>Difference in the spirometric variables between the dexamethasone and placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial blood gases</measure>
    <time_frame>Day 2 at 3200 m</time_frame>
    <description>Difference in arterial oxygen partial pressure, carbon dioxide partial pressure, and pH between the dexamethasone and placebo group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone 4 mg capsules, twice per day, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules twice per day, orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic obstructive pulmonary disease (COPD), GOLD grade 1-2

          -  Living at low altitude (&lt;800m)

        Exclusion Criteria:

          -  COPD exacerbation

          -  severe COPD, GOLD grade 3 or 4

          -  arterial oxygen saturation &lt;92% at low altitude (&lt;800 m)

          -  Diabetes, uncontrolled cardiovascular disease such as systemic arterial hypertension,
             coronary artery disease; previous stroke; pneumothorax in the last 2 months, untreated
             or symptomatic peptic ulcer disease, glaucoma, obstructive sleep apnea.

          -  Internal, neurologic or psychiatric disease that interfere with protocol compliance
             including current heavy smoking (&gt;20 cigarettes per day).

          -  pregnant or nursing patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konrad E Bloch, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, ZÃ¼rich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Talant M Sooronbaev, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Center of Cardiology and Internal Medicine</name>
      <address>
        <city>Bishkek</city>
        <zip>720040</zip>
        <country>Kyrgyzstan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kyrgyzstan</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2015</study_first_submitted>
  <study_first_submitted_qc>May 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2015</study_first_posted>
  <last_update_submitted>May 16, 2017</last_update_submitted>
  <last_update_submitted_qc>May 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>airway disease</keyword>
  <keyword>bronchitis</keyword>
  <keyword>emphysema</keyword>
  <keyword>lung</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

